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INTRODUCTION
1. INTRODUCTION
           Drug delivery systems are a magic tool for existing drug to enhance the safety
and  efficacy  of  the  drug  molecule  by  formulating  a  dosage  form  being  for  the
administration. Due to impaired swallowing ability, (dysphasia) it is common among
all age groups,  especially in elderly,  mainly it  is seen in swallowing conventional
tablets and capsules. (1) In  recent  years,  in accordance with changes in  lifestyle,  a
demand has arisen for the development of dosage forms that can be readily handled
and taken by many patients. (2) The oral fast‐disintegrating tablets is also known as fast
dissolve,  rapid  dissolve,  rapid  melt  and  quick  disintegrating  tablets,  however  the
function and concept of all these dosage forms are similar. (3) 
          By definition, a solid dosage form that dissolves or disintegrates quickly in the
oral cavity, resulting in solution or suspension without the need for the administration
of  water,  is  known  as  an  oral  fast  disintegrating  dosage  form. (4) According  to
European Pharmacopoeia,  the ODT should disintegrate in less than three minutes.
(5)Rapid disintegration of the drug will produce quick onset of action. Tablet dosage
form  is  mainly  composed  of  the  drug  and  excipients  such  as  a  diluent,  binder,
lubricant, disintegrant, and a glidant. (6)
          Lubricants are pharmaceutical excipients that improve the fluidity, filling
properties,  adhesiveness  and  plasticity  of  powders  and  are  indispensable  for
improving  the  quality  and  manufacturing  efficiency  of  solid  preparations. (7)
Lubricants help in reducing the friction between the powder bed and the die wall
during compression and ejection by interposing a film of low shear strength between
them. Some lubricants can also act as anti adherent, which prevents sticking of the
powder  to  the  punches  and  die.  Lubricant  also  has  profound  influence  on
disintegration  time,  hardness  and  drug  dissolution  therefore,  it  is  important  to
optimize the concentration of lubricant in the formulation.(8)  In solid pharmaceutical
formulations, magnesium stearate (Mg-St) is widely used as a hydrophobic lubricant.
The tensile strength of the tablet did not change when up to 3% of Mg stearate was
mixed into the formulation. (9)                  
          Short  disintegration time with good dispersibility is  the most  important
characteristics of fast  disintegrating tablets.  The necessity of an oral disintegrating
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tablet is to disintegrate within seconds, in limited amount of the water available in the
form of saliva. This demands the use of special type of disintegrants called as Super
disintegrants. (10) The Super disintegrants provide quick disintegration due to combined
effect of swelling and water absorption by the formulation. As an effect of swelling
properties  of  super disintegrant,  the wetted surface of  the carrier increases,  which
promote  wettability  and  dispensability  of  the  system  and  there  by  enhance  the
disintegration and dissolution. In solid pharmaceutical formulations crosscarmellose
sodium is widely used as a super disintegrant. (11) Disintegration by capillary action is
always  the  first  step.  When  we  put  the  tablet  into  suitable  aqueous  medium,  the
medium penetrates into the tablet and replaces the air adsorbed on the particles, which
weakens the intermolecular bond and breaks the tablet into fine particles. (12) 
          Direct compression is the easiest way to manufacture tablets with low cost,
conventional  equipments,  commonly available excipients  and a limited number of
processing steps leading to this technique is a preferable one. (13)  This technique can
now be applied to preparation of fast disintegrating tablets because of the availability
of  improved  excipients  especially super  disintegrants.  In  many oral  disintegrating
tablet  technologies  are  based  on  direct  compression,  the  addition  of  super
disintegrants affects the rate of disintegration and there by affects dissolution also. (14)
          Traditional experimental methods involves significant amount of time and
efforts to get meaningful results for a complex system. It is very much desirable to
obtain  an  acceptable  formulation  using  minimum  amount  of  time  and  material.
Factorial design is an efficient method of finding the relative significance of number
of  variables.  Optimization  procedure  involving  factorial  designs  and  analysis  of
response surfaces are powerful, efficient and also a systematic tool and has been used
in developing different oral dosage formulations. (15)
          Hypertension is a chronic illness that affects-50 million people in the United
States and 20% of the adult population in most countries. (16) Hypertensive patients are
at great risk for other cardiovascular diseases, including stroke, myocardial infarction,
and coronary artery disease, and congestive heart disease, renal insufficiency. (17)  The
goal of antihypertensive therapy is to “reduce the morbidity and mortality by the least
intrusive means possible”.  Calcium channel blockers are a diverse group of drugs
used to manage many different cardiovascular diseases. (18) Over the last two decades,
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calcium  channel  blockers  have  been  widely  prescribed  for  the  treatment  of
Hypertension, angina and supra ventricular arrythmiasis. (19)      
          Verapamil hydrochloride (VRP) is a phenyl alkyl amine derivative and first
clinically available and well known calcium antagonist.  (20) Calcium antagonists are
drugs which cause coronary and peripheral vasodilatation by reducing calcium influx
through the slow channels of vascular smooth muscle and cardiac cell membranes. (21)  
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2. REVIEW OF LITERATURE
          Sameer G.  Late et  al,  (6) investigated  the  Effects  of  calcium silicate
(disintegration-promoting  agent)  and  various  lubricants  on  an  optimized  β
cyclodextrin-based  fast-disintegrating  tablet formulation  and  effects  of  moisture
treatment were also evaluated at 75, 85 and 95% relative humilities. A two factor,
three levels (32) full factorial design was used to optimize concentrations of calcium
silicate and lubricant and reported that hardness was not affected at 75% moisture
treatment. At 85 and 95% moisture it increased hardness of the tablets; however at the
same time it negatively affected the disintegration time.
          Syed Azeem et al,  (22) Tablet is the most popular among all dosage forms
existing today because of  its  convenience  of  self  administration,  compactness and
easy manufacturing; however in many cases immediate onset of action is required
than  conventional  therapy.  To  overcome  these  drawbacks,  immediate  release
pharmaceutical dosage form has emerged as alternative oral dosage forms. There are
novel  types  of  dosage  forms that  act  very quickly after  administration.  The basic
approach used in development of tablets is by the use of super disintegrants like Cross
linked carboxy methyl cellulose (Croscarmeliose), Sodium starch glycolate (Primogel,
Explotab),  Poly vinyl  pyrrolidone (Polyplasdone) etc.  which provide instantaneous
disintegration of tablet after administration and also suggested that immediate release
formulations  are  similar  to  many  sustained  release  formulations  that  are  now
commonly available.
          Simone  Schiermeier et  al,  (23)  Investigate  to  check  whether  the  fast
disintegrating  tablets disintegrate  either  rapidly  in  water,  to  form  a  stabilized
suspension, or disperse instantaneously in the mouth to be swallowed without the aid
of water. A direct compression method was used to prepare these two types of tablets
containing coated ibuprofen as a high dosed model drug. The properties of the water
dispersible  tablet,  such  as  porosity,  hardness,  disintegration  time  and  increase  in
viscosity after dispersion, were investigated. And concluded, fast dispersible tablets
with acceptable hardness and desirable taste could be prepared within the optimum
region.
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Nadia Passerinia  et al, (24) studied the potential of waxes by preparing with
the ultrasonic spray congealing technique micro particles for controlling the in vitro
release of  Verapamil HCl was investigated. The results of this study show that by
selecting the type and the amount of the carriers,  micro particles with a spherical
shape and good encapsulation efficiency were observed.  These particles showed a
zero-order release for 8 h, without modifying the solid state properties of the drug.
Therefore,  waxy  micro  particles  prepared  by  the  ultrasonic  spray  congealing
technique are promising solvent-free devices for controlling the release of Verapamil
HCl.
Tamara Gonc¸ alves-Araújoa et al, (25) the objective of the present paper was
to study the existence of critical points governing the water and drug transport inside
HPMC hydrophilic matrix systems obtained with different polymer viscosity grades.
For  this  purpose,  extended  release  formulations  of  Verapamil  HCl,  have  been
prepared and studied. In order to estimate the percolation threshold, the behavior of
the kinetic parameters with respect to the volumetric fraction of each component at
time  zero,  was  studied.  From  the  point  of  the  percolation  theory,  the  optimum
concentration for all the studied polymers, to obtain a hydrophilic matrix system for
the controlled release of Verapamil HCl is higher than 20% (v/v) HPMC. Above 20%
(v/v)  HPMC, an infinite  cluster  of  excipients  would be formed,  ensuring uniform
hydration, maintaining integrity of the system and controlling the drug release.
L. Maggi et al, (26) Studied the evaluation of the stereo selective dissolution of
(±)  Verapamil HCl,  a  model racemic drug and, for this purpose,  different  matrix
compositions,  a  commercial  product  and  a  particular  delivery  device  have  been
considered. The delivery device, recently proposed for the delayed release of drugs,
consists of an active core containing the drug, coated by compression with different
types  of  chiral  polymeric  materials.  The  quantitative  determination  of  Verapamil
enantiomers released by these systems was carried out using a stereo specific HPLC
method. Hydroxypropylmethylcellulose, [cyclodextrin, hydroxypropyl] - cyclodextrin
and cross-linked amylose  did not  show any stereo  selective  dissolution properties
while  pectin,  galactomannan  and  scleroglucan  seemed  to  give  a  slightly  higher
dissolution  rate  of  the  R,  compared  with  the  S  enantiomer.  It  is,  however,  to  be
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verified whether these small differences in the release rate of the two enantiomers
detected 'in vitro' could lead to real in-vivo effects.
Müge Kılıçarslan et al,  (27) prepared the microspheres containing Verapamil
hydrochloride with Eudragit RS 100 by solvent evaporation method. And also with
solvent evaporation method where one of the parameters which affects the formation
and properties of the microspheres by the variations of drug/polymer ratios. And also
the effects of this parameter on the VRP loaded microspheres. And reported that the
variation  in  drug/polymer  ratios  might  have  an  influence  on  the  physical
characteristics of the microspheres and the increasing amount of polymer might be
result in decreased drug dissolve.
Emami J et al, (35) Studied about the controlled-release bucco adhesive tablets
of  Verapamil  hydrochloride  which  were  prepared  in  order  to  achieve  constant
plasma concentrations,  to  improve the  bioavailability by the  avoidance  of  hepatic
first-pass  metabolism,  and  to  prevent  frequent  administration.  The  maximum  bio
adhesive strength was observed in tablets formulated with a combination of CP-Na
CMC followed by CP-HPMC and Na CMC-HPMC. Decreasing the content of CP in
CP-HPMC tablets or Na CMC in CP-Na CMC or Na CMC, HPMC systems resulted
in decrease in detachment forces. Lower release rates were observed by lowering the
content of CP in CP-HPMC containing formulations or Na CMC in tablets which
contained CP-Na CMC or Na CMC-HPMC. The release behavior was non- Fickian
controlled by a combination of diffusion and chain relaxation mechanisms and best
fitted  zero-order  kinetics  and  concluded  that  the  bucco  adhesive  VPH  tablets
containing 53% CP and 13.3% HPMC showed suitable release kinetics (n = 0.78, K0
zero order release = 4.11 mg/h, MDT = 5.66 h) and adhesive properties and did not
show any interaction between polymers and drug based on DCS scanning. This bucco
adhesive system may be useful for buccal administration of VPH.
C. Ferrero et al, (11) Evaluated the efficiency of croscarmellose sodium (Ac-
Di-Sol) in a direct compression formulation containing a poorly water soluble drug
(albumin tan ate) at high dosage. Tablet properties evaluated were affected by both
variables,  while  compression  parameters  were  essentially  dependent  on  applied
pressure. The disintegration process was correlated with the densification behavior,
analyzed  by  means  of  Heckel  plots  and  force-displacement  curves,  and  tablet
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microstructure, measured by using a mercury porosimeter. The shortest disintegration
time was found for mixtures more prone to plastic deformation and densification at
same level of applied pressure. These mixtures also revealed a finer pore structure.
However, mixtures with higher yield pressures (i.e. less prone to plastic deformation)
showed  longer  disintegration  times  and  coarse  pore  structure.  The  different
rearrangement of disintegrant particles in powder mixture is suggested to explain the
dominant effect of the disintegrant bonding mechanism presented at a given mixture
composition. According to our results, consolidation mechanism and microstructure
analysis  should  be  performed  while  optimizing  disintegration  response  in  tablets
formulated with a disintegrant mainly acting by swelling mechanism.
C. Patil  et al,  (12) developed an ODT of Lamotrigine which is a recognized
drug for  epilepsy,  and evaluated the  effect  of  various super disintegrants on its
disintegration time and release profile was the prime objective of this research work.
Tablets  were  prepared  by  direct  compression  technique  using  3  different  super
disintegrants.  Sodium starch  glycolate,  Croscarmellose  sodium and Crosspovidone
XL-10 were used as super disintegrants in combinations to achieve optimum release
profile, disintegration time and hardness. The results of  in-vitro disintegration time
indicated that  the tablets dispersed rapidly in mouth within 8 s.  Dissolution study
revealed release rate of drug from the tablets was comparable with marketed tablet
formulation  of  Lamotrigine.  It  was  concluded  that  super  disintegrants  addition
technique  is  a  useful  method  for  preparing  orally  disintegrating  tablets  by direct
compression method.
          Kuno Y,Kojima M  et  al, (28) Carried a study to evaluate the  effect of
lubricants  on the characteristics of orally disintegrating (OD) tablets manufactured
using  the  phase  transition  of  sugar  alcohol.  OD  tablets  were  produced  by  direct
compression method. The effect of the type of lubricant on the tablet characteristics
was evaluated using magnesium stearate (Mg-St), sodium stearyl fumarate (SSF), and
talc as lubricants and concluded that consequently, talc was demonstrated to be the
most desirable lubricant for the preparation of OD tablets based on the principle of the
phase transition of sugar alcohol.
Jennifer  Wang  et  al,  (8) reviewed  the  theoretical  aspects  and  practical
considerations of lubrication in tablet compression. Properties of the materials that
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are often used as lubricants, such as magnesium stearate, in tablet dosage form were
summarized.  The  manufacturing  process  factors  that  may affect  tablet  lubrication
were  discussed.  As  important  as  the  lubricants  in  tablet  formulations  are,  their
presence  can  cause  some  changes  to  the  tablet  physical  and  chemical  properties.
Furthermore, a detailed review is provided on the methodologies used to characterize
lubrication  process  during  tablet  compression  with  relevant  process  analytical
technologies. Finally, the Quality-by-Design considerations for tablet formulation and
process development in terms of lubrication are discussed.
Takeaki  Uchimoto  et  al,  (9) Studied  the  effect  of  glycerin  fatty acid ester
(Poem TR-FB) concentrations on the dissolution rate of acetaminophen (APAP), the
dissolution and disintegration behaviors  of  APAP tablets  formulated using various
lubricants were examined. The change over time in the available surface area of APAP
(S(t)),  which  is  in  direct  contact  with  solvent,  was  also  analyzed  using  these
dissolution  data.  In  the  dissolution  tests,  a  retarded  dissolution of  APAP was  not
observed with TR-FB, whereas  magnesium stearate (Mg-St), which is widely used
as  a  lubricant,  retarded  the  dissolution.  However,  no  significant  difference  in  the
disintegration time between the two lubricants was observed. With regard to the time
course of the S(t), Mg-St at 0.1% gave a maximum surface area value at 9.19 min
(peak time); however, the profiles for APAP with Mg-St at greater than 0.5% showed
downward  curvature  indicating  a  gradual  decrease  in  surface  area  over  time.
Conversely, with TR-FB, even when its concentration was increased, the S(t) profile
for APAP had a maximum value that was more than twice that of APAP with that of
0.5–3.0% of Mg-St. Scanning electron microscopy (SEM) observations showed that
the differences in the dissolution rate and S(t) patterns between Mg-St and TR-FB
could be explained by differences in extensibility deriving from their morphology.
Therefore, it was concluded that TR-FB does not cause retardation of drug dissolution
and may prove to be a superior alternative lubricant to Mg-St.
          Chandrasekhar R  et al, (29) Made an attempt to  optimize FDTs using a
progressive  three-stage  approach.  Which  includes  hardness;  friability  and
disintegration  time  tests  were performed  on  the  formulations  at  each  stage  with
concentrations between 2% and 5% w/w, and were formulated at each concentration
as  single  and  combination  bloom strength  gelatin  using  75  and  225  BSGs.  And
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reported  that  the  addition  of  carbopol  974P-NF  resulted  in  the  enhancement  of
viscosity with a compromise of the hardness of the tablet,  whereas Pluronic F127
(6%)  showed  an increase  in  disintegration  time  and  viscosity  with  retention  of
mechanical properties.
          Rai V.K et al, (30) Developed a Raloxifene Hydrochloride immediate release
tablet by wet granulation technique. In order to obtain the best, optimized product six
different  formulations  with  different  filler,  binder,  disintegrant  and  lubricant  were
taken  as  variables.  Weight  variation,  thickness,  hardness,  friability,  disintegration
time,  in-vitro  release  and  pharmaceutical  assay  were  also  studied  as  response
variables. Andreported that sticking was observed when the formulation containing
stearic acid and sodium stearyl fumerate. However in the remaining four formulation
containing magnesium sterate, no sticking was observed. The formulation NP061 was
selected as an optimized product because different  physical  properties and in-vitro
release  profile  showed  best  comparable  with  reference  product.  Optimization  has
proven as an effective tool in product development.
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3. AIM AND OBJECTIVE
          Verapamil hydrochloride is a selective calcium channel blocker and is widely
used as an anti hypertensive drug. An attempt was made to prepare a fast disintegraing
tablet of Verapamil hydrochloride to reduce the lag time and provide faster onset of
action to get quick relief from hypertension. A fast disintegrating tablet form would
thus be advantageous as Verapamil hydrochloride is water soluble and its preparation
into fast disintegrating form would render it to disintegrate rapidly and there by result
in rapid absorption without any lag time.
          The objective of the present work is to prepare fast disintegrating tablet of
Verapamil hydrochloride by employing 2 factor 3 level (32) full factorial design with
nine  experimental  runs.  And  also  to  derive  a  statistical  models  and  evaluate  the
influence  of  crosscarmellose sodium (X1)  as  a  super  disintegrant  and magnesium
stearate (X2) as a lubricant and also to determine the disintegration time (Y1) and
hardness (Y2) is affected by adjusting two parameters namely crosscarmellose sodium
at concentration of 0, 15, 30 and magnesium stearate at concentration of 0, 10, 20
respectively in a fast disintegrating tablets.
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PLAN OF WORK
4. PLAN OF WORK
                  The scheme of the proposed work is as follows:
 Construction of standard curve of Verapamil Hydrochloride.
 Compatibility studies of drug and excipients by FT-IR spectral studies.
 Preformulation studies   
 Angle of repose.
 Determination of bulk density.
 Determination of tapped density.
 Compressibility index.
 Hauser’s ratio.
 Drug content uniformity test.
 Fabrication of fast disintegrating tablets of Verapamil Hydrochloride.
 Evaluation of physical parameters of fast disintegrating tablets.
  Thickness.
 Hardness.
 Friability.
 Weight variation.
 Drug content uniformity test.
 In-vitro  drug  release  studies  for  fast  disintegrating  tablets  of
Verapamil hydro chloride.
 In-vitro disintegration time.
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 In-vitro dissolution studies.
 Optimization of the best formulation using 32 factorial design.
 Evaluation of optimized fast disintegrating tablets by using ANOVA.
12
PROFILES
5. PROFILES
5.1. DRUG PROFILE
Verapamil hydrochloride
Category                                              : Phenyl alkyl amine calcium channel 
                                                                blocking agent.
Empirical formula                              : C27H38N2O4 HCl 
Molecular weight                                : 491.08
Chemical structure                             : 
Chemical name                                    : Benzeneacetonitrile,
                                                                α [3-[[2(3,4dimethoxyphenyl) 
                                                                ethyl]methylamino]propyl]-3,4-dimethoxy-α-
                                                                (1methylethyl) hydrochloride.  
Melting point                                       : 171ºC
pH                                                         : 5.0 - 6.5
Dosage and administration               : Oral administration and contain 
                                                                80mg of Verapamil Hydrochloride. (31)
Dosage form                                        : Tablets, capsules
Description                                         : White crystalline powder, practically odorless.
Solubility                                      : Soluble in water, freely soluble in           
                                                                chloroform, sparingly Soluble in alcohol,        
                                                                Practically insoluble in ether.
Brands Available                                : Isoptin, Calaptin, Veramil.
Mechanism of action (32)                           
          Verapamil hydrochloride exerts antihypertensive effects by inducing peripheral
vasodilation  and  reducing  peripheral  vascular  resistance  usually  without  reflex
tachycardia. 
           It is a calcium ion influx inhibitor that experts its pharmacological effects by
modulating  the  influx  of  ionic  calcium  across  the  cell  membrane  of  the  arterial
smooth muscle as well as in conductile and contractile myocardial cells.
Clinical uses (33)                                     
 Verapamil  hydrochloride is  used  to  treat  problems related to  the  heart and
circulation. It is a calcium channel blocker. 
 It works by relaxing and opening up the blood vessels, enabling blood to flow
more freely around the body. 
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 Benefits of being on this drug include reduced blood pressure, a more regular
heart rhythm and decreased likelihood of heart attack myocardial infarction in
patients who had a previous heart attack. 
 Mainly it is used for the treatment of hypertension and angina.
 It is used to control irregular heartbeats (arrhythmias).
Pharmacokinetics (34)                         
Absorption                                         
The extent of oral absorption of Verapamil hydrochloride is more than
90%. Due to the rapid biotransformation of Verapamil hydrochloride during its
first pass through the portal circulation, bioavailability ranges from 10 to 20%.
Verapamil  hydrochloride has  non-linear  pharmacokinetics  because  of  its
saturation  kinetics  (first  pass  metabolism)  which  leads  to  non-linear
absorption.  
Distribution                                          
          Verapamil HCl is widely distributed throughout body tissues; animal studies
suggest that drug distribution to target organs and tissues is different with parenteral
administration from that found after oral administration.
Metabolism                                           
          Verapamil undergoes extensive metabolism in the liver. Twelve metabolites
have  been  identified  in  plasma,  out  of  which  only  Nor  verapamil  was  found  in
significant amount whereas other metabolites were in trace amounts. Nor Verapamil
can  reach  steady-state  plasma  concentrations  approximately  equal  to  those  of
Verapamil HCl itself. The cardiovascular activity of nor Verapamil HCl appears to be
approximately 20% that of Verapamil HCl.
Elimination (35)                                          
          Approximately 70 to 80% of an administered dose is excreted as metabolites in
the urine and 16% or more in the feces. About 3 to 4% is excreted in the urine as
unchanged drug. 
Bioavailability                                       : 10 to 20%.
Peak plasma concentration                  : 1-2 hours. 
Biological half life                                  : 4-6 hours.
Elimination half life                             : 2.8to 7.4 hours
Excretion                                                : Urine
Volume of distribution                          : 2.4-6.2 L/Kg. 
Drug interactions (36)            
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 Aspirin: In a few reported cases, co-administration of Verapamil HCl with
aspirin has led to increased bleeding time greater than observed with aspirin
alone.
 Grapefruit juice: The intake of grapefruit juice may increase drug levels of
Verapamil HCl.
 Digitalis: Chronic Verapamil HCl treatment can increase serum digoxin levels
by 50 to 75% during the first week of therapy, and this can result in digitalis
toxicity.  Maintenance  and  digitalization  doses  should  be  reduced  when
Verapamil HCl is administered, and the patient should be carefully monitored
to avoid over or under digitalization.
 Antihypertensive Agents:  Verapamil  HCl administered concomitantly with
oral  antihypertensive  agents  (e.g.,  vasodilators,  angiotensin-converting
enzyme inhibitors, diuretics, beta blockers) will usually have an additive effect
on lowering the blood pressure.
 Quinidine: concomitant  use  of  Verapamil  HCl  and  quinidine  resulted  in
significant hypotension. 
Adverse reactions (37)
 Cardiovascular: angina  pectoris,  atrio-ventricular  dissociation,  chest  pain,
myocardial infarction.
 Digestive System: diarrhea, dry mouth, gastrointestinal distress.
 Nervous  System:  cerebro  vascular  accident,  confusion,  insomnia,  muscle
cramps, psychotic symptoms, 
 Skin: Arthralgia and rash, hair loss hyperkeratosis, sweating, urticaria.
 Special Senses: blurred vision, tinnitus.
 Urogenital: Gynecomastia,  impotence,  increased  urination,  spotty
menstruation.
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5.2. EXCIPIENT PROFILE
5.2.1. CROSSCARMELLOSE SODIUM
Non proprietary names                          
Bp                                                             : Carmellose sodium
Jp                                                              : Carmellose sodium
Ph Eur                                                      : Carmellose sodium
Usp                                                            : Carboxy methyl cellulose sodium
Synonyms                                                 : Sodium carboxy methyl cellulose; sodium 
                                                                      agent, suspending  agent, viscosity            
                                                                      Increasing agent and water absorbing 
                                                                      agent.
Applications in Pharmaceutical Formulations                       
           The main use of carboxy methyl cellulose sodium is in tablet formulations
where  it  is  used  as  a  binder,  diluent  and  disintegrant.  Although  carboxy  methyl
cellulose sodium is insoluble in water, it is an effective tablet disintegrant as it swells
to several times its original bulk on contact with water. Concentration up to 15%w/w
may  be  used  in  tablet  formulations;  above  this  concentration,  tablet  hardness  is
reduced.
Description                                                : Carboxy methyl cellulose sodium occurs 
                                                                      as a white to yellowish-white,         
                                                                      hygroscopic, fine powder.
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Typical Properties                                    
Acidity/Alkalinity                                     : pH =4.5-6.0 for a 1%w/w aqueous 
                                                                      dispersion.
Solubility                                                   
         Practically insoluble in acetone, chloroform, ethanol (95%), and ether. Insoluble
in water, but swells to twice its volume to form a suspension. Insoluble in 0.1 mol/ Lit
hydrochloric acid, but slightly soluble in 0.1mol/Lit sodium hydroxide.
Stability and Storage conditions             : Carboxy methyl cellulose sodium is a 
                                                                      stable, though hygroscopic material. It    
                                                                      should be stored in a well closed container
                                                                      in a cool, dry place.
5.2.2. MAGNESIUM STERATE
Non proprietary names
Bp                                                               : Magnesium sterate
Jp                                                                : Magnesium sterate
Ph Eur                                                        : Magnesii stearas
Usp                                                              : Magnesium sterate
Synonyms                                                   : Magnesium octadecanote ; stearic acid 
                                                                      Magnesium salt; octadecanoic acid,      
                                                                      Magnesium salt.
Chemical name                                          : Octadecanoic acid, magnesium salt
Empirical formula                                     : C36H70MgO4  
Molecular weight                                       : 591.34
Structural Formula                                   : [CH3 (CH2)16COO]2 Mg.
Functional Category                                 : Tablet and Capsule lubricant.
Description                                                 
          Magnesium sterate is a fine, white, precipitated or milled, impalpable powder of
low bulk density, having a faint odour of stearic acid and a characteristic taste .The
powder is greasy to the touch and readily adheres to the skin.
Typical Properties                                     
Density (bulk)                                            : 0.159 g/cm3
Density (tapped)                                         : 0.286g/cm3
Density (true)                                              : 1.092 g/cm3
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Solubility                                                    : Practically insoluble in ethanol, ethanol 
                                                                       (95%), ether and water; slightly soluble in
                                                                       warm benzene and warm ethanol (95%).
Applications in Pharmaceutical Formulations                        
          Magnesium stearate is widely used in cosmetics, foods, and pharmaceutical
formulations .It is primarily used as a lubricant in capsule and tablet manufacture at
concentrations between 0.25-5.0%.It is also used in barrier creams.
Stability and Storage conditions              : Magnesium stearate is stable and should  
                                                                       Be Stored in a well-closed container in a  
                                                                       cool and dry place.
Safety                                                          
           Magnesium stearate is widely used as a pharmaceutical excipient and is
generally regarded as being non toxic following oral administration. However oral
consumption  of  large  quantities  may  result  in  some  laxative  effect  or  mucosal
irritation.
5.2.3. LACTOSE MONOHYDRATE
Non proprietary names
Bp                                                                : Lactose monohydrate
Jp                                                                 : Lactose
Ph Eur                                                         : Lactose monohydricum
Usp                                                               : Lactose monohydrate
Chemical name                                           : O-β-D-Galactopyranosyl-(1-4)-α-D-
                                                                        glucopyranose monohydrate
Structural Formula                                   :
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                                                                         Inhale tablet binder; tablet and capsule 
                                                                         diluent.
 Applications in Pharmaceutical Formulations                    
          Lactose is widely used as a filler or diluent in tablets and capsules, and to a
more limited extent in lyophilized products and infant formulas. Lactose is also used
as  a  diluent  in  dry  powder  inhalation.  Various  lactose  grades  are  commercially
available that have different physical properties such as particle size distribution and
flow characteristics.
          Other applications of lactose include use in lyophilized products, where lactose
is added to Freeze-dried solutions to increase plug size and aid cohesion. Lactose is
also used in combination with sucrose (approximately 1:3) to prepare sugar coating
solutions.
          Direct  compression  grades  of  lactose  monohydrate  are  available  as
granulated/agglomerated  α-lactose  mono  hydrate,  containing  small  amounts  of
anhydrous lactose.
Description                                                   
          In the solid state ,Lactose appears as various isomeric forms, depending on the
crystallization and drying conditions, i.e.-Lactose mono hydrate-Lactose anhydrous,
and stable α-Lactose anhydrous.
Typical Properties                                          
Angle of repose                                            : 330 for pharmatose DCL 15; 320 for 
                                                                         tablettose 70 and T  tablettose 80.
Density (true)                                               : 1.545 g/cm3 (α-Lactose mono hydrate)
Melting point                                               : 201-2020c (for dehydrated α-Lactose 
                                                                        mono hydrate)
Moisture content                                         : Lactose mono hydrate contains 
                                                                         approximately 5%w/w water  of 
                                                                         crystallization and range of 4.5-
                                                                         5.5% w/w water content.
5.2.4. MICROCRYSTALLINE CELLULOSE
Nonproprietary names
BP                                                                 : Microcrystalline cellulose
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USP                                                               : Microcrystalline cellulose
Synonyms                                                     : Avicel; cellulose gel; crystalline 
                                                                         cellulose; E460; Emocel; Fibrocel; 
                                                                         Tabulose;  Vivacel. 
Chemical Name                                           : Cellulose
Chemical structure                                     :
                                                           
Empirical Formula                                     : (C 6H 10O 5) n                  
Molecular Weight                                       : 36000
Functional category                                    : Adsorbent; suspending agent; tablet and  
                                                                        capsule diluent; tablet disintegrant 
Description                                                          
          Micro crystalline cellulose is purified, partially depolymerized cellulose that
occurs  as  a  white,  odorless,  tasteless,  crystalline  powder  composed  of  porous
particles. It is commercially available in different particle sized and moisture grades
which have different properties and applications.
  Applications in Pharmaceutical Formulations                         
          Micro crystalline cellulose is widely used in pharmaceuticals, primarily as
binder/diluents in oral tablet and capsule formulations where it is used in both wet
granulation and direct compression processes. In addition to its use as binder/diluents,
micro crystalline cellulose also has  some lubricant and disintegrant properties that
make it useful in tableting.
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5.2.5. MANNITOL
Non proprietary names                                               
Bp                                                                 : Mannitol
 Jp                                                                 : Mannitol
Ph Eur                                                          : Mannidex
Usp                                                                : Manicol
Synonyms                                                     : Cordycepic Acid; E421; NCI-C50362; 
                                                                         Manita; Manitol; Manna Sugar;  
                                                                         Mannite;  d-Mannitol; Mannitolum.
Empirical formula                                       : C6H14O6
Molecular weight                                         : 182.2
Structural Formula                                     :    
Functional Category                                    : Diluent for lyophilized preparations; 
                                                                          Sweetening agent; tablet and capsule  
                                                                          diluent; tonicity agent.
Description                                                   
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          A white  odorless  crystalline  powder  or  granules  with  a  sweet  taste
approximately as sweet as glucose and half as sweet as sucrose and imparts a cooling
sensation in the mouth.
Typical Properties
Density (bulk)                                               : 0.7g/cm3
Density (tapped)                                            : 0.8g/cm3
Melting point                                                : 166° to 168°.
Solubility                                                       : It is soluble in alkali and ethanol (95%) 
                                                                          1 in 83, and glycerin 1 in 18.Insoluble 
                                                                          in ether.
Pharmaceutical Applications                      : Tablet diluent-10-90%
Stability and Storage conditions                 
          It is stable in the dry state and in aqueous solutions. The bulk material must be
stored in well closed containers in a cool and dry place.
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MATERIALS
6. MATERIALS
6.1. INGREDIENTS USED
Table 1: Ingredients used for the experiment
S. No Name of the ingredient Manufacturer/Suppliers
1. Verapamil HCl Micro labs, Hosur.
2. Crosscarmellose Sodium National chemie, Gujarath.
3. Magnesium Sterate Loba chemie pvt.ltd, Mumbai.
4. Micro crystalline cellulose E.Merck (India) limited, Mumbai.
5. Lactose Loba chemie pvt.ltd, Mumbai.
6. Mannitol Spectrum chemie, Cochin.
6.2. INSTRUMENTS USED
Table 2: Instruments used for the experiment
S.No Name of the instrument Manufacturing company
1. Digital balance Shimadzu ELB 300
2. Tablet hardness tester Monsanto tablet hardness tester
3. Friability tester Electro lab ET-2 friability test
apparatus, India.
4. Dissolution apparatus USP XXIII veego tablet dissolution apparatus,
Chennai.
5. Double beam UV
spectrophotometer
Perkin Elmer Lambda-25 UV/VIS
spectrometer.
6. Rotary tablet punching machine Chamunda pharma machinery
Pvt.ltd, Ahmadabad
7. FT-IR spectrophotometer Perkin Elmer spectrum RX1 FT-IR
spectrophotometer.
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METHODOLOGY
7. METHODOLOGY
7.1. PRE FORMULATION STUDIES
          Pre formulation testing is an investigation of physical and chemical properties
of drug substance alone and when combined with pharmaceutical excipients. It is the
first step in the rational development of dosage form.
7.1.1. Compatibility studies (Fourier transform infrared spectroscopic studies)(38)
          One of the requirement for the selection of suitable excipients or carrier for
pharmaceutical formulation is its compatibility. Therefore in the present work a study
was carried out by using FT-IR spectrophotometer to find out if there is any possible
chemical  interaction  of  Verapamil  hydrochloride  with  magnesium  stearate  and
crosscarmellose sodium.
Procedure
          To study the compatibility of various formulation excipients with Verapamil
hydrochloride  solid  admixtures  were  prepared  by  mixing  the  drug  with  each
formulation excipients separately in the ratio of 1:1 and stored in air tight containers
at  30±20  /65±5%  RH.  The  solid  admixtures  were  characterized  using  Fourier
transform infrared spectroscopy (FT-IR).
7.1.2. Construction of standard curve for Verapamil hydrochloride
          Verapamil hydrochloride can be estimated spectrophotometrically at 279 nm as
it obeys Beer's-Lambert's law limit in the range of 5-30 µg/ml.
Preparation of reagents
Preparation of 0.1 N HCl
          Dissolve 8.5 ml of concentrated HCl in 1000 ml of distilled water.
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Preparation of standard drug solution
Stock solution
        100 mg of Verapamil hydrochloride was dissolved in 100 ml of 0.1 N HCl, to get
a solution of 1000 µg/ml concentration.
Standard solution
          10 ml of stock solution was made to 100 ml with 0.1 N HCl thus giving a
concentration of 100 µg/ml. Aliquot of standard drug solution ranging from 0.5 ml, 1
ml, 1.5 ml, 2 ml and 2.5 ml were transferred into 10 ml volumetric flask and were
diluted up to the mark with 0.1 N HCl. Thus the final concentration ranges from 5-25
µg/ml. Absorbance of each solution was measured at 279 nm against 0.1 N HCl as a
blank. A plot of concentrations of drug versus absorbance was plotted.
7.1.3. Characterization of Powder (39)
          Prior to compression, blend was evaluated for their characteristic parameters
such as:
i. Angle of repose
ii. Bulk density
iii. Hauser's Factor
iv. Compressibility Index
i). Angle of repose
          The angle of repose of granules, was determined by the fixed funnel and
freestanding cone method, where by accurately weighed blend (5gm) were carefully
poured through the funnel with its tip at 2 cm height (h) until the apex of the conical
heap so formed just reached the tip of the funnel. The mean diameter (r), of the base
for  powder  cone was measured  and  angle  of  repose  (θ)  was  calculated  using the
following equation.
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Tan θ =h/r
θ =tan-1 (h/r)
Where,   θ =Angle of repose
h=Height
r=Radius
Table 3: USP official limits of angle of repose
Angle of repose (degrees) Flow
25-30 Excellent
31-35 Good
36-40 Fair
41-45 Passable
46-55 Poor
56-65 Very poor
>66 Very, very poor
            
ii). Bulk density
          Both loose bulk density and tapped bulk density were determined, where by a
quantity (20gm) of blend from each formula, previously lightly shaken to break any
agglomerates  in  cylinder.  After  the initial  volume was observed,  the cylinder  was
allowed to full under its own weight onto have a surface from the height of 2.5 cm at
2 second intervals. The tapping was continued until no further change in the volume
was noted loose bulk density (LBD) and tapped bulk density (TBD) were calculated
using the following formulas.
LBW=Weight of the powder/volume of the packing
TBW=Weight of the powder/tapped volume of the packing
iii). Hauser's Ratio
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          It indicates the flow properties of the powder and it measured by the ratio of TD
to the BD  
Hauser's Ratio=TD/BD
                                    
Table 4: USP official limits of Hauser’s ratio
Hauser's Ratio property
1.00-1.11 Excellent
1.12-1.18 Good
1.19-1.25 Fair
1.26-1.34 Passable
1.35-1.45 Poor
1.46-1.59 Very poor
>1.60 Very very poor
1v). Compressibility index
          To analyze flow ability, the Carr's index was calculated on the basis of the LBD
and TBD. The compressibility index of the blend was determined by Carr's index.
Carr's index (%) = 100 [TD-BD/TBD]
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Table 5: USP official limits of compressibility index
% Carr 's index properties
<10 Excellent
11-15 Good
16-20 Fair
21-25 Passable
26-31 Poor
32-37 Very poor
>38 Very very poor
7.2. FABRICATION OF FAST DISINTEGRATING TABLETS
Direct compression method (40)
                        The composition of fast  disintegrating tablet  of Verapamil
hydrochloride is showed in table no-6. Weighed quantities of Verapamil hydrochloride
along with appropriate  concentration of   Crosscarmellose  sodium,  Lactose,  Micro
crystalline cellulose, and Mannitol were weighed and sieved through sieve no:40 and
mixed in geometric proportion in a dry and clean mortar for about 25 minutes. Then
Magnesium stearate was added after passing the above blend through sieve no: 60 and
mixed well for 2 minutes.
                           The above lubricated blend was compressed into tablets using 8 mm
single  tablet  punching  machine.  Then  the  fabricated  tablets  were  evaluated  for
thickness, hardness, friability, weight variation test, drug content uniformity,  In-vitro
disintegration time and In-vitro dissolution studies.
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Table 6: Composition of Fast Disintegrating Tablet
Formulation
code
Drug
(mg)
Crosscarmellose
sodium(mg)
Magnesium
sterate(mg)
Lactose
(mg)
Micro
crystalline
cellulose(mg)
Mannitol
(mg)
F1 80 0 0 10 20 90
F2 80 5 5 10 20 80
F3 80 10 10 10 20 70
F4 80 20 15 10 20 65
F5 80 30 20 10 20 40
F6 80 10 0 10 20 80
F7 80 15 10 10 20 65
F8 80 0 5 10 20 85
F9 80 30 10 10 20 50
7.3. PHYSICOCHEMICAL EVALUATION OF FAST DISINTEGRATING
TABLETS
          The properties of the fast disintegrating-tablets such as Hardness, Friability,
Weight variation & drug content uniformity were studied.
7.3.1. Thickness
          The thickness of the tablets was determined by using a Vernier calipers, mean
and SD was calculated.
7.3.2. Hardness test
          For each formulation, the hardness of 3 tablets were determined by using a
Monsanto hardness tester, mean and SD were calculated.
7.3.3. Friability test
          For each formulation, 6 tablets were weighed. The tablets were placed in a
friabilator (Roche friabilator) and subjected to 25 rpm in 4 minutes. The tablets were
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de dusted and reweighed. The friability was calculated as the percentage of weight
loss.
F=100(1-Wo/Wt)
                                 Where,    
                           Wo = Weight of tablets before friability test
                           Wt = Weight of tablets after friability test
7.3.4. Weight variation test
          To study weight variation, of tablet of each formulation were weighed using an
electronic balance and the test was performed according to the USP official limits of
percentage deviation of tablet are presented in the table no 7.
%Maximum positive deviation= (WH-A/A) ×100
%Minimum negative deviation= (A-WL/A) ×100
             Where,       WH= Highest weight in mg
                                WL= Lowest weight in mg
                                A= Average weight of tablet in mg
Table 7: USP official limits of weight variation test
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Average  weight  of
tablet (mg)
Maximum  percentage
difference allowed
130 or less 10
130-324 7.5
More than 324 5
7.3.5. Drug content uniformity
Standard preparation
          An accurately weighed amount of pure Verapamil hydrochloride (100 mg) was
taken and transferred into 100 ml volumetric flask. It was dissolved and made up to
volume with 0.1 N HCl and absorbance was measured at 279 nm.
Sample preparation
          Tablets were weighed individually then placed in a mortar and powdered with a
pestle. An amount of powdered Verapamil hydrochloride (100 mg) was extracted in
0.1 N HCl. The absorbance was measured at 279 nm after suitable dilution.
Calculation
          The amount of Verapamil hydrochloride present in tablet can be calculated
using the formula
At/AsXSw/100X100/StXAv
                    Where,
                             At=Absorbance of sample preparation
                             As=Absorbance of standard preparation 
                              Sw=Weight of Verapamil hydrochloride working standard
                             St=Weight of Verapamil hydrochloride tablet (mg)
                              Av=Average weight of tablet (mg)
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7.4. IN-VITRO DRUG RELEASE STUDIES
In-Vitro disintegration time (41)
          The  disintegration  time  of  the  tablets  was  determined  as  per  Indian
pharmacopoeial  monograph.  The  test  was  carried  out  using  tablet  disintegration
apparatus.
             Six tablets from each batch were placed and one liter of distilled water was
used  as  the  disintegration  medium.  The  time  required  to  obtain  complete
disintegration of all the six tablets were noted.
In-Vitro Dissolution time (42)
             Medium        : 0.1 N HCl (pH 1.2)
              Apparatus    : USP, XXIII-type 2 (Paddle)
              RPM            : 30
              Temperature: 37o ±0.5o C
              Volume        : 900 ml
Procedure
          The release of Verapamil hydrochloride from the compressed fast disintegrating
tablets were studied up to 20 minutes in 900 ml of 0.1 N HCl (pH 1.2) as dissolution
medium using a USP dissolution paddle assembly at  30 rpm and 37o  ±0.5o  C. An
aliquot (1 ml) was withdrawn at periodic intervals of 1st, 2nd, 4th, 6th, 8th, 10th, 15th  and
20th minutes and diluted to 10 ml with the dissolution medium, and drug content was
determined by UV-Visible spectrophotometer at 279 nm. An equal volume of fresh
dissolution medium was replaced to maintain the dissolution volume.
          Dissolution studies were performed 3 times for a period of 20 minutes and the
mean value was taken. Cumulative percentage of drug release was calculated using an
equation obtained from a standard curve.
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7.5 Statistical Optimization Technique (43)
The optimization was designed statistically using 32 factorial design. A 3-level
full-factorial design consists of 9 full-factorial design points; according to the model,
9 experiments were conducted in total.   This  design generally involves dependent
variable Y and independent or controlled variable X.  The 2 independent formulation
variables  are  Y1,  Y2  and  the  2  dependent  formulation  variables  are  X1,  X2  are
selected.
For this study X1, crosscarmellose sodium and X2 magnesium stearate were
selected.  The levels of independent variables are shown in Table 8. The dependent
variables were Y1, disintegration time andY2, hardness was shown in Table 9.
The  results  obtained  from  the  experiment  were  statistically  analyzed  for
response variables by using Design Expert 8.07 version (Stat-Ease Inc., Minneapolis,
Minnesota). The statistical model incorporating interactive and polynomial terms was
used to evaluate the response. (44)
Y = b0 + b1X1 + b2X2 + b12X1X2 + b11X1X1 + b22X2X
Thus the optimized formulation is prepared and evaluated for its disintegration time 
and hardness characteristics.
STATISTICAL OPTIMIZATION
Table 8: Independent Variables (45)
C
ode
Variables Low level ( -1 ) Medium Level ( 0 ) High  Level (+1)
X1
Crosscarmellos
e sodium
0 15 30
X2
Magnesium
Stearate
0 10 20
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Table 9:   Dependant / Response Variables (6)
Code Dependent Variables
Y1 Disintegration Time
Y2 Hardness
Table 10: Composition of Fast Disintegrating Tablet of Verapamil HCl as Per 32
Factorial Design
Formulatio
n code
Dru
g
(mg
)
Crosscarmellos
e sodium(mg)
Magnesiu
m
sterate(mg
)
Lactos
e
(mg)
Micro
crystalline
cellulose(mg
)
Mannito
l
(mg)
Ff1 80 0 0 10 20 90
Ff2 80 0 10 10 20 80
Ff3 80 0 20 10 20 70
Ff4 80 15 0 10 20 75
Ff5 80 15 10 10 20 65
Ff6 80 15 20 10 20 55
Ff7 80 30 0 10 20 60
Ff8 80 30 10 10 20 50
Ff9 80 30 20 10 20 40
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RESULTS
8. RESULTS
8.1. PREFORMULATION STUDIES
8.1.1. Compatibility studies (Fourier transform infrared spectroscopic studies)
          Compatibility studies were performed using FTIR spectrophotometer. The
spectrum of pure drug and physical mixture of drug and excipients were studied. 
          The peaks obtained in the spectra of each formulation correlates with the peaks
of drug spectrum. This indicates that the drug was compatible with the formulation
components. The spectra for all formulations were shown in Fig 1 to Fig 4.
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8.1.2. Standard curve of Verapamil hydrochloride
          The standard curve of Verapamil hydrochloride was determined in 0.1 N HCl
(pH 1.2) by using UV-Visible spectrophotometer at 279 nm. Graph was plotted by
taking absorbance (nm) on X-axis verses concentration (µg/ml) on Y-axis and it is
follows the Beer's law. The results were shown in table 11.
    Table 11: Standard curve results of Verapamil hydrochloride in 0.1N HCl
Concentration (µg/ml) Absorbance (nm)
0 0
5 0.140
10 0.299
15 0.441
20 0.570
25 0.710
30 0.820
Slope 0.029
R2 0.998
0 5 10 15 20 25 30 35
0
0.1
0.2
0.3
0.4
0.5
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0.7
0.8
0.9
f(x) = 0.03x + 0.01
R² = 1
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Fig 5: Standard curve results of Verapamil hydrochloride in 0.1N HCl
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8.1.3. Powder Characterization 
          The blended powder of different formulations was evaluated for angle of
repose,  bulk density,  tapped density,  compressibility index and Hauser's  ratio.  The
results of these evaluations are as follows.
ɵAngle of repose ( )
           The angle of repose for the blended was shown in the table 12. The entire
formulation blend was found to be in the range 210.62'±1.030 to 260 .05'±2.847. Thus
it indicating that the angle of repose of the formulated blend is within pharmacopeial
limits. 
Bulk density and tapped density
          Bulk and tapped densities are used for the measurements of compressibility
index are shown in the table 13. The bulk density and tapped density ranged from
0.69±0.011 to 0.76±0.025 and 0.76±0.020 to 0.88±0.026.
Compressibility index (Carr's index)
          Compressibility index is an important measure that can be obtained from the
bulk and tapped densities. The values are shown in the table 13. The compressibility
index is in the range from 5.99±0.588 to 15.22±2.473.
Hauser's ratio
           It indicates the flow properties of the powder and is measured by the ratio of
tapped density to the bulk density. The Hauser's ratio range from are shown in the
table 13.The values are in the range from 1.05±0.005 to 1.18±0.037.
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Table 12: Angle of repose (θ) of all formulations
Formulation
code
Height* (cm) Radius* (cm) h/r* θ =tan-1(h/r) *
F1 1.51±0.020 3.06±0.251 0.48±0.030 25.93±1.409
F2 1.54±0.020 3.30±0.200 0.46±0.027 24.69±0.950
F3 1.50±0.015 3.76±0.152 0.39±0.062 21.62±1.030
F4 1.52±0.011 3.62±0.208 0.42±0.079 22.77±0.970
F5 1.62±0.025 3.33±0.407 0.49±0.060 26.05±2.847
F6 1.58±0.011 3.47±0.293 0.45±0.035 24.52±1.665
F7 1.51±0.026 3.73±0.152 0.40±0.015 21.96±0.752
F8 1.52±0.015 3.43±0.416 0.44±0.047 23.88±2.283
F9 1.50±0.015 3.43±0.351 0.43±0.045 23.56±2.176
*Each value represents the mean ± S.D. of three experiments.
Table 13: Preformulation evaluation of all formulations
Formulation
code
Bulk
Density*
Tapped
Density*
Hauser's
Ratio*
Carr's Index*
F1 0.73±0.025 0.79±0.035 1.08±0.010 7.41±0.275
F2 0.72±0.015 0.84±0.023 1.16±0.041 14.28±2.680
F3 0.76±0.025 0.88±0.026 1.15±0.030 13.63±1.660
F4 0.74±0.017 0.88±0.049 1.18±0.037 15.22±2.473
F5 0.70±0.025 0.76±0.020 1.08±0.021 8.44±1.071
F6 0.73±0.015 0.78±0.017 1.05±0.005 5.99±0.588
F7 0.72±0.025 0.80±0.042 1.11±0.025 10.27±1.834
F8 0.69±0.011 0.83±0.024 1.06±0.219 17.00±1.856
F9 0.74±0.020 0.82±0.043 1.10±0.064 9.75±1.869
*Each value represents the mean ±S.D. of three experiments
8.2. PHYSICAL EVALUATION PARAMETERS OF FAST DISINTEGRATING
TABLETS
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          Verapamil hydrochloride fast disintegrating tablets were evaluated for various
physical parameters namely thickness, hardness, friability, weight variation, wetting
time and uniformity of drug content etc.
8.2.1. Hardness and Thickness Test
          The hardness of different formulations is ranged from 3.2±0.145 Kg/cm2 to
5.4±0.350 Kg/cm2 as shown in the table 14.
          The thicknesses of the tablets are ranged from 3.6±0.012 mm to 3.6±0.068 mm
as shown in the table 14.  
Table 14: Hardness and Thickness of the Tablets
Formulation 
code
Hardness of the
tablet (kg/cm2)*
Thickness of the
tablet (mm)*
F1 5.4±0.350 3.6±0.068
F2 5.3±0.36 3.7±0.040
F3 4.9±0.510 3.6±0.015
F4 4.6±0.05 3.6±0.008
F5 3.2±0.145 3.6±0.012
F6 4.4±0.195 3.6±0.010
F7 4.5±0.095 3.5±0.018
F8 5.3±0.090 3.6±0.008
F9 4.3±0.141 3.6±0.008 
*Each value represents the mean ±S.D. of three experiments
8.2.2. Friability test
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               Depending upon the ingredients of different formulations, the weight of
tablet was fixed. In each formulation, weight variation was within limit. Mostly the
variation was within ± 1%. All  the formulations  exhibited less  than 1% friability
which was within the limit.
Table 15: Friability data of the tablets
Formulation code Weight of 10
tablets
before test
Weight of 10
tablets after
test
Friability
F=100(1-
w0/wt)
F1 1.994 1.990 0.412
F2 1.987 1.983 0.226
F3 1.992 1.989 0.313
F4 1.972 1.968 0.212
F5 1.967 1.962 0.251
F6 1.951 1.946 0.256
F7 1.996 1.992 0.413
F8 2.010 2.005 0.249
F9 1.981 1.976 0.234
8.2.3. Weight variation test
           The percentage weight variations for all formulations are performed. Both the
formulations passed weight variation test  as per the pharmacopial  limits of 5% as
shown in the table 16.
Table 16: Weight variation test of the tablets
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S.NO F1 F2 F3 F4 F5 F6 F7 F8 F9
1 199.2 200.3 198.4 199.2 198.6 200.7 198.2 200.3 198.8
2 198.4 202.2 198.5 198.5 199.4 200.5 198.5 199.7 198.7
3 198.6 199.4 201.4 198.3 199.5 201.8 198.6 198.7 199.7
4 198.9 198.9 198.4 198.5 198.6 199.6 199.6 198.5 198.5
5 197.4 200.9 198.2 199.2 199.2 199.5 201.2 198.5 202.5
6 198.3 199.4 199.5 198.5 198.4 199.9 198.4 200.4 199.8
7 199.3 200.2 199.7 198.4 198.7 202.6 199.5 198.3 202.3
8 200.2 198.9 198.6 200.4 198.5 199.8 198.3 198.6 197.6
9 197.6 199.2 197.9 199.4 200.2 201.4 199.6 201.7 202.3
10 198.9 199.4 201.0 198.6 200.6 199.2 199.4 200.3 199.8
11 198.3 199.9 200.4 198.7 198.2 202.7 200.3 201.7 198.5
12 198.6 201.4 200.3 199.2 198.5 199.6 198.5 198.6 199.4
13 201.4 199.6 198.9 199.3 198.6 201.5 202.5 198.6 199.9
14 198.8 198.4 196.4 196.9 200.3 202.4 200.4 202.3 198.7
15 198.2 196.6 199.2 198.1 200.5 201.3 200.2 202.1 201.4
16 200.4 199.5 198.9 199.5 198.4 199.7 198.4 198.6 201.7
17 201.2 198.2 198.6 201.8 198.9 199.4 198.7 199.6 199.5
18 199.6 198.7 198.7 199.3 199.3 199.6 199.4 199.4 199.3
19 198.9 198.2 199.3 198.7 199.7 198.9 199.6 199.3 198.7
20 200.4 199.7 201.5 199.7 198.9 199.7 198.9 198.7 198.8
Avg.
Weight*
199.1 199.4 199.1 199.0 199.1 200.4 199.4 199.6 199.7
Mean 1.100 1.228 1.253 0.977 0.759 1.215 1.102 1.331 1.457
%Max.
positive
deviatio
n
1.15 1.00 1.20 1.40 0.75 1.13 1.55 1.35 1.40
%Min.
negative
deviatio
n
0.85 1.40 1.35 1.05 0.45 0.74 0.60 0.55 0.60
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8.2.4. Drug content uniformity
               The content uniformity test for Verapamil hydrochloride was carried out.
The results were found to be 98.64±0.402 to 99.49±0.199.The results were found to
be within the USP specification limits (90% -  110%).  It  shows that  the drug was
distributed uniformly throughout the tablets is shown in table 17.
Table 17: Drug content uniformity of the tablets
Formulation
Code
Drug content
analysis*
No. of tablets
outside 90% to
110% limit
F1 98.64±0.402 NIL
F2 98.89±0.277 NIL
F3 99.33±0.42 NIL
F4 99.48±0.350 NIL
F5 98.99±0.327 NIL
F6 98.89±0.278 NIL
F7 99.49±0.199 NIL
F8 99.24±0.188 NIL
F9 99.31±0.277 NIL
*Each value represents the mean ±S.D. of three experiments
8.3. IN VITRO DRUG RELEASE CHARACTERISTICS
8.3.1. In-Vitro disintegration time data of the tablets
                The  In-Vitro  disintegration time was in the range of 20.36±0.550 to
248.23±0.13.
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Table 18: In-vitro disintegration time of tablets
*E ac
h
8.3.2. IN VITRO DRUG RELEASE FOR FAST DISINTEGRATING TABLETS
OF VERAPAMIL HYDROCHLORIDE
The fast disintegrating tablets were prepared by using super disintegrant, lubricant and
in  vitro drug  release  studies  were  carried  out  in  trial  (n=3)  basis  for  total  nine
formulations (F1-F9). 
               The release of Verapamil hydrochloride from the fast disintegrating tablets
were  studied  in  900  ml  of  0.1  N  HCl  for  20  min  by  using  USP XXIII  paddle
dissolution apparatus at 50 rpm and 370±0.50 C. Drug content was determined by UV-
Visible  spectrophotometer  at  279  nm. Cumulative  percentage  of  drug release  was
calculated  by using  an  equation  obtained  from a  standard  curve.  The  dissolution
studies  were  performed  3  times  for  a  period  of  20  min  and  mean  values  were
calculated by one way ANOVA in Graph pad software package. The results of these
studies were shown in table 19 to 28.
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Formulation Code In-vitro disintegration time(sec)*
F1 248.23±0.13
F2 66.08±0.18
F3 44.83±0.21
F4 39.76±0.04
F5 20.36±0.550
F6 33.06±0.80
F7 38.46±0.901
F8 162.10±0.14
F9 28.08±0.22
Table 19: Dissolution profile of formulation F1
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.099 3.694 33.24 41.56±0.409
2 0.113 4.200 37.80 47.26±1.244
4 0.126 4.685 42.16 52.71±2.407
6 0.142 5.293 47.64 59.55±1.141
8 0.154 5.721 51.49 64.37±1.009
10 0.181 6.709 60.38 75.48±0.924
15 0.209 7.756 69.80 87.26±1.176
20 0.229 8.488 76.39 95.49±0.402
*Each value represents the mean ±S.D. of three experiments.
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Table 20: Dissolution profile of formulation F2
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.113 4.203 37.83 47.29±0.566
2 0.131 4.857 43.72 54.65±0.945
4 0.162 6.028 54.25 67.82±1.260
6 0.178 6.605 59.44 74.31±0.843
8 0.197 7.321 65.89 82.37±1.636
10 0.229 8.500 76.50 95.63±1.114
*Each value represents the mean ±S.D. of three experiments.
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Table 21: Dissolution profile of formulation F3
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.110 4.254 38.28 47.86±0.930
2 0.128 4.748 42.73 53.42±0.778
4 0.163 6.070 54.63 68.29±0.621
6 0.179 6.661 59.95 74.94±0.916
8 0.199 7.392 66.52 83.16±0.597
10 0.230 8.525 76.72 95.91±0.883
*Each value represents the mean S.D. of three experiments.
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Table 22: Dissolution profile of formulation F4
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.117 4.353 39.18 48.98±0.690
2 0.133 4.932 44.39 55.49±0.463
4 0.165 6.139 55.25 69.07±1.460
6 0.181 6.736 60.63 75.79±0.535
8 0.203 7.547 67.92 84.91±0.623
10 0.231 8.559 77.03 96.29±0.931
*Each value represents the mean ±S.D. of three experiments.
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Table 23: Dissolution profile of formulation F5
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.127 4.705 42.35 52.94±0.916
2 0.148 5.495 49.45 61.82±0.880
4 0.183 6.785 61.07 76.34±0.778
6 0.202 7.489 67.40 84.26±0.196
8 0.220 8.172 73.55 91.94±0.216
10 0.237 8.792 79.13 98.92±0.903
*Each value represents the mean ±S.D. of three experiments.
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Table 24: Dissolution profile of formulation F6
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.121 4.505 40.55 50.69±0.877
2 0.140 5.211 46.90 58.63±0.195
4 0.171 6.336 57.03 71.29±0.093
6 0.187 6.934 62.40 78.01±0.624
8 0.208 7.720 69.48 86.85±0.187
10 0.232 8.625 77.63 97.04±0.787
*Each value represents the mean ±S.D. of three experiments.
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Table 25: Dissolution profile of formulation F7
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.117 4.359 39.23 49.04±1.286
2 0.136 5.039 45.35 56.69±1.002
4 0.167 6.202 55.82 69.78±1.047
6 0.183 6.799 61.19 76.49±0.594
8 0.206 7.640 68.76 85.96±2.113
10 0.232 8.605 77.44 96.81±1.041
*Each value represents the mean ±S.D. of three experiments.
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Table 26: Dissolution profile of formulation F8
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.101 3.744 33.69 42.12±1.064
2 0.118 4.388 39.49 49.37±0.319
4 0.129 4.781 43.03 53.79±0.395
6 0.156 5.793 52.14 65.18±0.156
8 0.167 6.200 55.80 69.76±1.054
10 0.188 6.988 62.89 78.62±0.974
15 0.214 7.944 71.49 89.37±1.003
20 0.231 8.558 77.02 96.28±1.065
*Each value represents the mean ±S.D. of three experiments.
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Table 27: Dissolution profile of formulation F9
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.122 4.536 40.82 51.03±0.419
2 0.142 5.288 47.59 59.49±0.791
4 0.177 6.559 59.03 73.79±0.046
6 0.198 7.367 66.30 82.88±0.395
8 0.213 7.913 71.22 89.03±1.002
10 0.234 8.696 78.26 97.83±0.143
*Each value represents the mean ±S.D. of three experiments.
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Table 28: Comparative In-Vitro release data (%) for Verapamil Hydrochloride Fast
Disintegrating Tablet Formulations (F1-F9)
Time
(min) Formulation code And Cumulative % of drug release*
F1 F2 F3 F4 F5 F6 F7 F8 F9
0 0 0 0 0 0 0 0 0 0
1 41.56 47.29 47.86 48.98 52.94 50.69 49.04 42.12 51.03
2 47.26 54.65 53.42 55.49 61.82 58.63 56.69 49.37 59.49
4 52.71 67.82 68.29 69.07 76.34 71.29 69.78 53.79 73.79
6 59.55 74.31 74.94 75.79 84.26 78.01 76.49 65.18 82.88
8 64.37 82.37 83.16 84.91 91.94 86.85 85.96 69.76 89.03
10 75.48 95.63 95.91 96.29 98.92 97.04 96.81 78.62 97.83
15 87.26 - - - - - - 89.37 -
20 95.49 - - - - - - 96.28 -
*Each value represents the mean ±S.D. of three experiments.
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8.4. STATISTICAL OPTIMIZATION TECHNIQUE BY ANOVA
The optimization was designed statistically using 32 factorial design. A 3-level
full-factorial design consists of 9 full-factorial design points; according to the model,
9 experiments were conducted in total.   This  design generally involves dependent
variable Y and independent or controlled variable X.  The 2 independent formulation
variables Y1, Y2 and 2 dependent formulation variables X1, X2 were selected.
For  this  study,  X1Crosscarmellose  Sodium and  X2 magnesium stearate  are
selected.  The levels of independent variables are shown in Table 29. The dependent
variables are Y1 Disintegration Time and Y2 hardness are shown in Table 29.
The  results  obtained  from  the  experiment  are  statistically  analyzed  for
response variables by using Design Expert 8.07 version (Stat-Ease Inc., Minneapolis,
Minnesota). The statistical model incorporating interactive and polynomial terms are
used to evaluate the response:
Y = b0 + b1X1 + b2X2 + b12X1X2 + b11X1X1 + b22X2X2
 The regression coefficients for each term in the regression were shown in 
Table 30 to 37.
EFFECT OF FORMULATION VARIABLES DISINTEGRATION TIME
In the case of Y1 (Disintegration Time) b1, b12, b11, b22 were found to be 
significant with interaction of b2.The b2 is not significant since P>0.05.When the X1 
(Crosscarmellose Sodium) level is increased Y1 (Disintegration Time) also increased. 
The X2 (Magnesium Sterate) slightly influence the Y1 (Disintegration Time).
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EFFECT OF FORMULATION VARIABLES ON HARDNESS
In the case of Y2 (hardness), all the coefficients b1, b12, b11 were found to be
significant with interaction of b2 and b22.The b2 and b22 were not significant since
P>0.05.Whan  we  increase  the  b2  concentration  it  does  not  influence  on  the  Y2
(Hardness).When we increase the b1 concentration it will influence slightly on Y2
(Hardness).
8.4.1. PARAMETERS OF OPTIMIZED FORMULATIONS
In-Vitro disintegration time and Hardness Data in a 32 Full Factorial Design
          The disintegration time of different formulations are ranged from 18±0.015 to
280±0.084.  And the hardness  was in the range of 3.1±0.078 Kg/cm2 to 5.3±0.084
Kg/cm2 as shown in the table 29.
Table 29: In-vitro disintegration time and hardness data of the optimized tablets
FORMULATION
CODE
CODED VALUES DISINTEGRATION
TIME (SEC)*
HARDNESS
(kg/cm2)*X1 X2
Ff1 -1 -1 332±0.021 5.3±0.084 
Ff2 -1 0 280±0.084 5.2±0.015
Ff3 -1 1 208±0.015 5.1±0.036
Ff4 0 -1 29±0.056 4.4±0.058
Ff5 0 0 40±0.031 4.7±0.199
Ff6 0 1 28±0.083 4.3±0.005
Ff7 1 -1 18±1.000 3.2±0.151
Ff8 1 0 30±0.036 4.5±0.161
Ff9 1 1 20±0.051 4.2±0.049
*Each value represents the mean ±S.D. of three experiments
Table 30: Factorial fit:  Disintegration Time Vs X1 and X2
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Estimated regression coefficients for Disintegration Time using
Data In coded units
Term  Coefficient T P
Constant 39.56 63.83 0.0030
X1 -125.33 235.47 0.0006
X2 -20.50 6.30 0.0869
X1*X2 31.50 0.0513 0.0000
X1*X1 115.67 0.0038 0.0000
X2*X2 -10.83 0.4995 0.0075
Table 31: Model Summary Statistics
Std. Dev. 20.01
Mean 109.44
PRESS 18.28
C.V% 14636.96
R-Squared 0.9907
Adjusted R-Squared 0.9752
Predicted R-Squared 0.8865
Adeq.Precision 19.202
Table 32
Estimated regression coefficients for Disintegration Time
using un coded units
Term Coefficient
Constant 39.565555
X1 -125.33333
X2 -20.500000
X1*X2 31.500000
X1*X1 115.67666
X2*X2 -10.83333
Regression coefficient 
Y1 =39.56-125.33X1-20.50X2+31.50X1X1 +115.67 X12 -10.83X22
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Fig.18: Interaction Plot of Disintegration Time Vs Crosscarmellose Sodium (X1),
Mag.   Stearate(X2)
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Table 33: Factorial fit:  Hardness Vs X1 and X2
Estimated regression coefficients for  Hardness using Data In
coded units
Term  Coefficient T P
Constant 4.53 7.07 0.0264
X1 -0.63 13.39 0.0106
X2 0.15 0.75 0.4194
X1*X2 -0.0945 10.0425 0.0044
X1*X1 0.3969 179.2921 0.0001
X2*X2 0.0225 0.5625 0.1758
Table 34: Model Summary Statistics
Std. Dev. 0.42
Mean 4.53
PRESS 9.35
C.V% 2.74
R-Squared 0.7021
Adjusted R-Squared 0.6028
Predicted R-Squared 0.2419
Adeq.Precision 6.401
Table 35
Estimated regression coefficients for Hardness using un
coded units
Term Coefficient
Constant 4.53333
X1 -0.63333
X2 0.15000
X1*X2 -0.094999
X1*X1 0.4011068
X2*X2 0.0225
Regression coefficient 
Y2 =   4.53-0.63X1+0.15X2-0.0945X1X1 +0.3969 X12 +0.0225X22
65
Design-Expert® Software
Factor Coding: Actual
Hardness
Design Points
5.3
3.1
X1 = A: Crosscarmelose Sodium
X2 = B: Magnesium Stearate
-1.00 -0.50 0.00 0.50 1.00
-1.00
-0.50
0.00
0.50
1.00
Hardness
A: Crosscarmellose Sodium
B
: 
M
a
gn
e
s
iu
m
 
S
te
a
ra
te
4
4.55
4.80904
4.18413
Fig. 19: Contour plot of Hardness Vs Crosscarmellose Sodium (X1), Mag. Stearate
(X2)
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Fig. 20:  Surface Plot of Hardness Vs Crosscarmellose Sodium (X1), Mag. Stearate
(X2)
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Fig.21: Interaction Plot of Hardness Vs Crosscarmellose Sodium (X1), Mag. Stearate
(X2)
66
Table 36: The regression coefficients for each term in the regression model are
summarized as follows
POLYNOMIAL EQUATIONS R2
Y1 =  39.56-125.33X1-20.50X2+31.50X1X1 +115.67 X12
-10.83X22
0.9907
Y2 = 4.53-0.63X1+0.15X2-0.0945X1X1 +0.3969 X12
+0.0225X22
0.7021
Table 37: Results of analysis of variance for measured response
Parameters Degree of freedom Sum of Square Mean Sum of Square
For Disintegration Time
Regression 5 1.277E+005 25546.69
Residual 3 1200.78 400.26
Total 8 1.289E+005 25946.95
For Hardness
Regression 2 2.54 1.27
Residual 6 1.08 0.18
Total 8 3.62 1.45
OPTIMIZATION 
The  polynomial  equations  generated  for  the  dependent  variables  and
independent variables are shown in the Table 36.  The process was optimized for the
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responses Y1 and Y2.  The optimized formulation was arrived at by the disintegration
time and hardness to obtain the desired levels of X1 and X2. It was illustrated by the
results  that  the hardness was not influenced.  To verify the reproducibility,  a new
formulation was prepared (Table 38).  
Table 38: Formulation of finally optimized batch Ff7
Composition Weight in mgs
Verapamil HCl 80
Crosscarmellose sodium 30
Magnesium stearate 0
Lactose 10
Micro crystalline
cellulose
20
Mannitol 60
Table 39: The dependent variables calculated for the optimized formulation are
tabulated as follows
Dependent
variables
Trial 1 Trial 2 Trial 3 AVG ± S.D.
Disintegratio
n Time in sec 17 18 19 18±1.000
Hardness in
kg/cm2 3.1 3.4 3.2 3.2±0.151
IN  VITRO DRUG  RELEASE FOR  OPTIMIZED  FAST DISINTEGRATING
TABLETS OF VERAPAMIL HYDROCHLORIDE
Table 40: Dissolution profile of formulation Ff1
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
68
1 0.103 3.844 34.60 43.25±0.219
2 0.116 4.316 38.84 48.56±0.36
4 0.131 4.863 43.76 54.71±0.336
6 0.152 5.648 50.84 63.55±0.342
8 0.166 6.167 55.50 69.38±0.234
10 0.181 6.707 60.36 75.46±0.163
15 0.209 7.759 69.83 87.29±0.612
20 0.232 8.599 77.39 96.74±0.32
*Each value represents the mean ±S.D. of three experiments.
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Table 41: Dissolution profile of formulation Ff2
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.103 3.824 34.42 43.03±0.2013
69
2 0.118 4.374 39.36 49.21±0.091
4 0.125 4.656 41.90 52.38±0.474
6 0.152 5.640 50.76 63.45±0.532
8 0.162 6.020 54.18 67.73±0.274
10 0.179 6.661 59.95 74.94±0.289
15 0.204 7.581 68.23 85.29±0.346
20 0.229 8.489 76.40 95.51±0.34
*Each value represents the mean ±S.D. of three experiments.
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Table 42: Dissolution profile of formulation Ff3
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
70
1 0.104 3.886 34.97 43.72±0.392
2 0.118 4.402 39.62 49.53±0.475
4 0.134 4.984 44.86 56.08±0.364
6 0.154 5.735 51.61 64.52±0.258
8 0.166 6.178 55.60 69.51±0.249
10 0.185 6.868 61.81 77.27±0.346
15 0.211 7.848 70.64 88.30±0.623
20 0.232 8.621 77.59 96.99±0.464
*Each value represents the mean ±S.D. of three experiments.
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Table 43: Dissolution profile of formulation Ff4
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
71
0 0 0 0 0
1 0.123 4.576 41.18 51.48±0.440
2 0.141 5.249 47.24 59.06±0.395
4 0.173 6.420 57.78 72.23±0.371
6 0.190 7.070 63.63 79.54±0.606
8 0.205 7.610 68.49 85.62±0.605
10 0.233 8.643 77.79 97.24±0.44
*Each value represents the mean ±S.D. of three experiments.
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Table 44: Dissolution profile of formulation Ff5
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
72
0 0 0 0 0
1 0.118 4.390 39.51 49.39±0.285
2 0.137 5.095 45.85 57.32±0.622
4 0.165 6.145 55.31 69.14±0.392
6 0.180 6.685 60.16 75.21±0.285
8 0.200 7.420 66.78 83.48±0.457
10 0.230 8.539 76.85 96.07±0.392
*Each value represents the mean ±S.D. of three experiments.
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Table 45: Dissolution profile of formulation Ff6
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Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.124 4.598 41.38 51.73±0.26
2 0.143 5.302 47.72 59.65±0.520
4 0.177 6.558 59.02 73.78±0.487
6 0.190 7.064 63.57 79.47±0.429
8 0.206 7.663 68.96 86.21±0.290
10 0.234 8.692 78.23 97.79±0.268
*Each value represents the mean ±S.D. of three experiments.
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Table 46: Dissolution profile of formulation Ff7
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.131 4.870 43.81 54.79±0.499
2 0.150 5.568 50.11 62.64±0.298
4 0.186 6.920 62.28 77.86±0.423
6 0.202 7.510 67.59 84.49±0.372
8 0.222 8.225 74.03 92.54±0.294
10 0.238 8.841 79.57 99.47±0.342
*Each value represents the mean ±S.D. of three experiments.
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Table 47: Dissolution profile of formulation Ff8
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.121 4.512 40.60 50.76±0.231
2 0.140 5.189 46.70 58.38±0.325
4 0.167 6.187 55.68 59.61±0.344
6 0.185 6.871 61.84 77.30±0.346
8 0.204 7.562 68.06 85.08±0.145
10 0.232 8.614 77.52 96.91±0.143
*Each value represents the mean ±S.D. of three experiments.
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Table 48: Dissolution profile of formulation Ff9
Time
(min)
Absorbance
(nm)
Concentration
(µg/ml)
Amount of
drug release
Cum % of drug
release*
0 0 0 0 0
1 0.125 4.646 41.81 52.27±0.435
2 0.145 5.383 48.44 60.56±0.614
4 0.177 6.559 59.03 73.79±0.561
6 0.202 7.494 67.44 84.31±0.982
8 0.217 8.039 72.35 90.44±0.862
10 0.237 8.794 79.15 98.94±0.274
*Each value represents the mean ±S.D. of three experiments.
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Table 49: Comparative Optimized In-Vitro release data (%) for Verapamil
Hydrochloride Fast Disintegrating Tablet Formulations (Ff1-Ff9)
Time
(min)
Formulation code And Cumulative % of drug release*
Ff1 Ff2 Ff3 Ff4 Ff5 Ff6 Ff7 Ff8 Ff9
0 0 0 0 0 0 0 0 0 0
1 43.03 43.03 43.72 51.48 49.39 51.73 54.79 50.76 52.27
2 49.21 49.21 49.53 59.06 57.32 59.65 62.64 58.38 60.56
4 52.38 52.38 56.08 72.23 69.14 73.78 77.86 59.61 73.79
6 63.45 63.45 64.52 79.54 75.21 79.47 84.49 77.30 84.31
8 67.73 67.73 69.51 85.62 83.48 86.21 92.54 85.08 90.44
10 74.94 74.94 77.27 97.24 96.07 97.79 99.47 96.91 98.94
15 85.29 85.29 88.30 - - - - - -
20 95.51 95.51 96.99 - - - - - -
*Each value represents the mean ±S.D. of three experiments.
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DISCUSSION
9. DISCUSSION
The  present  investigation  was  undertaken  to  find  out  the  effect  of  super
disintegrating  agent  and  lubricant  on  optimized  fast  disintegrating  tablets  of
Verapamil hydrochloride.
          The compatibility study of drug and excipients were studied by FTIR. The FT-
IR spectral analysis showed that there was no appearance or disappearance of any
characteristic peaks of pure drug Verapamil hydrochloride in the physical mixture of
drug  and  with  excipients,  which  confirmed  that  there  is  no  chemical  interaction
between drug and excipients.
           The  tablets  were  prepared  by  direct  compression  method  using
Crosscarmellose  sodium  as  a  super  disintegrant  and  Magnesium  stearate  as  a
lubricant. The mixture of all formulation before compression were evaluated for angle
of repose,  loose bulk density,  tapped bulk density,  compressibility index and drug
content. The angle of repose value ranged from 210.62'±1.030 to 260  .05'±2.847.The
results were found to be below 300 and hence the blend was found to have good flow
ability.  Bulk and tapped densities were used for the measurement of Compressibility
index.  The LBD (loose bulk density) and TBD (tapped bulk density) ranged from
0.69±0.011  to  0.76±0.025  and  0.76±0.020  to  0.88±0.026  respectively.   The
compressibility index (%) was then calculated from the LBD and TBD and it ranged
from 5.99±0.588 to 15.22±2.473. The blend was found to have free flowing property
as the result was found to be below 20%.  The Hauser's ratio ranged from 1.05±0.005
to  1.18±0.037.  The  value  was  found  to  be  below  1.2  which  is  suitable  for  free
flowing.
          The tablets were prepared by using direct compression method and the tablets
of all formulation were subjected to various evaluation parameters such as hardness,
thickness, friability, weight variation, drug content, in-vitro disintegration time and in-
vitro dissolution study.
          The results of all these tests were found to be within the limits. The hardness of
tablets  in  all  batches  ranged  from  3.2±0.145  Kg/cm2 to  5.4±0.350  kg/cm2.  The
thickness of the tablets was uniform in all formulations and ranged from 3.6±0.012
mm to 3.6±0.068 mm. All the formulations (F1-F9) passed the weight variation test as
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per the pharmacopeial  limit of  ± 5%. All  the formulations exhibited less than 1%
friability which was within the limit.  Drug content was also found to be uniform
among the all formulations and ranged from 98.64±0.402% to 99.49±0.199%. And in-
vitro  disintegration  time  was  found  to  be  in  the  range  from  20.36±0.550  to
248.23±0.13.
The drug release studies were performed on the prepared formulations (F1-F9)
using 0.1N HCL for  20min.Table  19 to  28  enlists  the  comparatives  In-vitro  drug
release data for  F1 to  F9 formulations.  The percentage drug release of  Verapamil
hydrochloride  for  all   formulations  showing  95.49%,  95.63%,  95.91%,  96.29%,
98.92%, 97.04%, 96.81%, 96.28 and 97.83% respectively.  In  the above results  all
formulations release drug within 10 minutes except F1 and F8 because of the absence
of disintegrating agent. From the above results, the F5 formulation showed faster and
maximum drug release than the other formulations. The comparative release of all the
six formulations was plotted on the Fig 15.
          Factorial design is an efficient method of finding the relative significance of
number of variables and their interaction on the response. Here 32 full factorial design
was applied to best formulation (F5) to determine the effect of disintegrating agent
and lubricant on fast disintegrating tablets of Verapamil hydrochloride. Magnesium
stearate  decreases  the  wettability  of  the  matrix  and  thus,  may  increase  the
disintegration time of an optimized formulation. Hence,  concentration of  lubricant
was  selected  as  one  of  the  independent  variables  for  the  experimental  design.
Crosscarmellose Sodium, a disintegration-promoting agent was selected as another
variable  which  may  decrease  the  disintegration  time  of  the  optimized  fast
disintegrating tablets.
The values of the X1 and X2 are associated with the effect of variables Y1 and
Y2 response. Coefficients with more than one factor represent an interaction effect
(e.g.  X1X2)  while  those  with  higher  order  (e.g.  X22) terms  denote  quadratic
relationships. A positive sign signifies a synergistic effect while a negative sign stands
for an antagonistic effect. Only statistically significant (p  < 0.05) coefficients were
retained in the equations.
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Disintegration time and hardness values for all the formulations (Ff1-Ff9) are
varied from 18±1.000 to 332±0.021 and 3.2±0.151 to 5.3±0.084 kg/cm2 respectively.
These  results  indicate  that  the  selected  variables  have  strong  influence  on
disintegration time and hardness of the fast disintegrating tablets. Analysis of variance
for  the  responses  (ANOVA)  indicated  that  the  assumed  regression  models  were
significant and valid for each of the responses (p<0.05).
From the analysis of the fitted data we can conclude that the crosscarmellose
sodium (X1) had an significant influence on the disintegration time and the hardness
of  the  fast  disintegrating  tablet  formulation,  and  the  optimum  concentration  of
lubricant have only influence on the disintegration time and the hardness of the fast
disintegrating  formulation  because  disintegration  time  increased  with  increased
concentration of the lubricant, magnesium stearate (X2). Disintegration was delayed
due to the general agreed observation that magnesium stearate forms a hydrophobic
membrane on the surface  of  the powder  particles.  Hence,  disintegration time will
increase with the increased concentration of magnesium stearate. These results were
quiet interesting and contradictory to the general  notion that the tablet hardness is
known to decrease with increase in the magnesium stearate concentration. Several
authors have demonstrated that because of high extensibility of magnesium stearate, it
spreads over the surface of the powder particles. This in turn prevents bonding among
powder particles,  giving low tensile  strength and decrease in  tablet  hardness with
increase in the concentration of magnesium stearate.
Based on this study, magnesium stearate was chosen as a lubricant at 1.5%
concentration as it gave optimum hardness value with low disintegration time. The
drug  release  studies  were  also  performed  on  the  prepared  formulations  (Ff1-Ff9)
using  0.1N  HCL  for  20min.The  percentage  drug  release  of  optimized  fast
disintegrating Verapamil hydrochloride for all  formulations were within the limits.
From the above results Ff7 is taken as best formulation.
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10. CONCLUSION
 Fast  disintegrating tablet  is a promising approach with a view of obtaining
faster  action  of  the  drug  and  would  be  advantageous  in  comparison  to
currently  available  conventional  forms.  Fast  disintegrating  tablets  of
Verapamil hydrochloride  were prepared by direct compression method using
croscarmellose sodium as a super disintegrant and magnesium stearate as a
lubricant. In vitro drug release from the tablets shows significant improvement
in drug dissolution. By the comparative statistical data F5 was taken as the
best formulation. 
 The application of full factorial design was useful in evaluating influence of
disintegrating  agent  (crosscarmellose  Sodium)  concentration  and  lubricant
(magnesium  stearate)  concentration  on  an  optimized  fast  disintegrating
formulation  of  Verapamil  hydrochloride.  From  the  statistical  design,
crosscarmallose Sodium concentration had an influence on the disintegration
time and tablet hardness. 1.5% magnesium stearate concentration was selected
as an optimum concentration where it has an influence on disintegration time
and hardness of the optimized fast disintegrating tablet formulation. From the
in-vitro drug release studies Ff7 was taken as the best formulation. Further it is
recommended to perform in-vivo studies for the fast disintegrating tablets of
Verapamil hydrochloride.
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